David Lebowitz

Gavin Clark-Gartner

Jessica Fye

Ryan Deschner

Michael Ulz

Ryan Mcelroy

Brian Skorney

Catherine Okoukoni

Dae Gon Ha

Jonathan Wolleben

Jon Wolleben

Josh Schimmer

Rohit Bhasin

Selena Zhang

Swayampakula Ramakanth

Thomas Yip

Timur Ivannikov

- MIRA Pharmaceuticals completed the **acquisition of SKNY Pharmaceuticals**, adding **$5 million in marketable securities** and expanding its drug development pipeline with **SKNY-1**, an oral drug candidate targeting **obesity and nicotine addiction**.  **[1759425_b8352b013a1b498a8d6f66f4430cf7fd]** 
- The company continues to advance **Ketamir-2**, which showed **favorable Phase 1 trial results** with good safety and tolerability and notably no central nervous system (CNS) side effects.  **[1759425_b8352b013a1b498a8d6f66f4430cf7fd]** 
- MIRA has resolved a **Nasdaq compliance issue** related to stock sales and the merger, though it remains under monitoring.  **[1759425_b8352b013a1b498a8d6f66f4430cf7fd]** 
- Analysts currently rate MIRA stock as a **Buy** with a **target price of $17.00**.  **[1759425_b8352b013a1b498a8d6f66f4430cf7fd]**

MIRA Pharmaceuticals Completes SKNY Acquisition

Mirum Pharmaceuticals (MIRM)